Literature DB >> 17435555

Electrochemotherapy: aspects of preclinical development and early clinical experience.

John O Larkin1, Christopher G Collins, Simon Aarons, Mark Tangney, Maria Whelan, Seamus O'Reily, Oscar Breathnach, Declan M Soden, Gerald C O'Sullivan.   

Abstract

OBJECTIVE: To develop an optimized, reproducible system of electrochemotherapy, and to investigate its clinical application in patients with cutaneous or subcutaneous recurrences of inoperable or progressive disease recalcitrant to current anticancer treatments.
BACKGROUND: Electrochemotherapy is the application of electric pulses to tumor tissue, rendering the cell membranes permeable to otherwise impermeant or poorly permeant anticancer drugs. This facilitates a potent local cytotoxic effect. STUDY
DESIGN: The optimal parameters for electrical pulses and bleomycin concentration were obtained in vitro and then applied to tumors derived from 4 histologically distinct human cancer cell lines (7860, PC3, OE19, MCF-7) established in athymic nude mice. Comparison was made with tumors that received bleomycin alone, electric pulses alone, and untreated controls. The optimized electrochemotherapy was then applied to patients with cutaneous or subcutaneous tumors, of any histologic type, recurrent or metastatic and unresponsive to standard chemotherapy and/or radiotherapy regimens. Tumors were assessed at monthly intervals to determine response to the treatment.
RESULTS: In vivo: Using the optimal parameters ascertained in vitro, all tumors treated by electrochemotherapy with bleomycin (n = 24) had significantly regressed (P < 0.001, all 4 lines) compared with control tumors (n = 72). Twelve tumors completely regressed (50%) following a single application, with 12 partial regressions (50%). Clinical: In 30 patients (111 tumors), none of the treated tumors progressed. Sixty percent of tumors (66 of 111) showed complete regression, 22% (24 of 111) partial response, and 18% (21 of 111) no change. Electrochemotherapy was more effective in smaller tumors (<3 cm), 71% (64 of 90) showing complete regression, 20% (18 of 90) partial response, and 9% (8 of 90) no change.
CONCLUSIONS: Electrochemotherapy parameters optimized in vitro are applicable in vivo. This treatment is effective in athymic nude mice for all histologic types indicating a nonimmunologic mode of action. In clinical application, electrochemotherapy is an effective, safe, and reproducible therapy. Patients with cutaneous or subcutaneous tumors previously refractory to surgical intervention, systemic chemotherapy, and/or radiotherapy responded successfully irrespective of histologic type.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17435555      PMCID: PMC1877027          DOI: 10.1097/01.sla.0000250419.36053.33

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  40 in total

1.  Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture.

Authors:  B Poddevin; S Orlowski; J Belehradek; L M Mir
Journal:  Biochem Pharmacol       Date:  1991-12-11       Impact factor: 5.858

2.  Bleomycin-mediated electrochemotherapy of metastatic melanoma.

Authors:  L F Glass; M L Pepine; N A Fenske; M Jaroszeski; D S Reintgen; R Heller
Journal:  Arch Dermatol       Date:  1996-11

3.  Electrochemotherapy of spontaneous mammary tumours in mice.

Authors:  J Belehradek; S Orlowski; B Poddevin; C Paoletti; L M Mir
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

4.  Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice.

Authors:  G Sersa; M Cemazar; D Miklavcic
Journal:  Cancer Res       Date:  1995-08-01       Impact factor: 12.701

Review 5.  Bleomycin: revival of an old drug.

Authors:  L M Mir; O Tounekti; S Orlowski
Journal:  Gen Pharmacol       Date:  1996-07

6.  Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial.

Authors:  M Belehradek; C Domenge; B Luboinski; S Orlowski; J Belehradek; L M Mir
Journal:  Cancer       Date:  1993-12-15       Impact factor: 6.860

7.  Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized.

Authors:  O Tounekti; G Pron; J Belehradek; L M Mir
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

8.  Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host's defenses.

Authors:  L M Mir; S Orlowski; B Poddevin; J Belehradek
Journal:  Eur Cytokine Netw       Date:  1992 May-Jun       Impact factor: 2.737

9.  Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy.

Authors:  R Heller; M J Jaroszeski; L F Glass; J L Messina; D P Rapaport; R C DeConti; N A Fenske; R A Gilbert; L M Mir; D S Reintgen
Journal:  Cancer       Date:  1996-03-01       Impact factor: 6.860

10.  Antitumor electrochemotherapy: new advances in the clinical protocol.

Authors:  C Domenge; S Orlowski; B Luboinski; T De Baere; G Schwaab; J Belehradek; L M Mir
Journal:  Cancer       Date:  1996-03-01       Impact factor: 6.860

View more
  26 in total

1.  Calcium electroporation induces tumor eradication, long-lasting immunity and cytokine responses in the CT26 colon cancer mouse model.

Authors:  Hanne Falk; Patrick F Forde; Marie Lund Bay; Uma Maheswari Mangalanathan; Pernille Hojman; Declan M Soden; Julie Gehl
Journal:  Oncoimmunology       Date:  2017-03-17       Impact factor: 8.110

2.  Scaling relationship and optimization of double-pulse electroporation.

Authors:  Mohamed M Sadik; Miao Yu; Mingde Zheng; Jeffrey D Zahn; Jerry W Shan; David I Shreiber; Hao Lin
Journal:  Biophys J       Date:  2014-02-18       Impact factor: 4.033

3.  Multidisciplinary approach to breast angiosarcoma in an elderly patient: Repeated local relapses and significant objective responses.

Authors:  Carmela Mocerino; Giuseppe Iannaci; Patrizia Sapere; Rossella Luise; Silvestro Canonico; Antonio Gambardella
Journal:  Int J Immunopathol Pharmacol       Date:  2016-02-12       Impact factor: 3.219

4.  Bleomycin electrochemotherapy in elderly metastatic breast cancer patients: clinical outcome and management considerations.

Authors:  Luca G Campana; Sara Galuppo; Sara Valpione; Antonella Brunello; Cristina Ghiotto; Alessia Ongaro; Carlo R Rossi
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-03       Impact factor: 4.553

Review 5.  Electrochemotherapy in head and neck cancer: A review of an emerging cancer treatment.

Authors:  Armando De Virgilio; Massimo Ralli; Lucia Longo; Patrizia Mancini; Giuseppe Attanasio; Francesca Atturo; Marco De Vincentiis; Antonio Greco
Journal:  Oncol Lett       Date:  2018-07-12       Impact factor: 2.967

6.  Electrochemotherapy of mouse sarcoma tumors using electric pulse trains with repetition frequencies of 1 Hz and 5 kHz.

Authors:  G Sersa; S Kranjc; J Scancar; M Krzan; M Cemazar
Journal:  J Membr Biol       Date:  2010-07-04       Impact factor: 1.843

Review 7.  The controversial role of electrochemotherapy in head and neck cancer: a systematic review of the literature.

Authors:  Riccardo Lenzi; Luca Muscatello; Alberto Maria Saibene; Giovanni Felisati; Carlotta Pipolo
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-02-24       Impact factor: 2.503

8.  Towards treatment planning and treatment of deep-seated solid tumors by electrochemotherapy.

Authors:  Damijan Miklavcic; Marko Snoj; Anze Zupanic; Bor Kos; Maja Cemazar; Mateja Kropivnik; Matej Bracko; Tjasa Pecnik; Eldar Gadzijev; Gregor Sersa
Journal:  Biomed Eng Online       Date:  2010-02-23       Impact factor: 2.819

Review 9.  Electrochemotherapy in Breast Cancer - Discussion of the Method and Literature Review.

Authors:  Mateusz Wichtowski; Dawid Murawa; Katarzyna Kulcenty; Karolina Zaleska
Journal:  Breast Care (Basel)       Date:  2017-12-03       Impact factor: 2.860

10.  Electrochemotherapy in melanoma patients: a single institution experience.

Authors:  Corrado Caracò; Ugo Marone; Ester Simeone; Antonio Maria Grimaldi; Gerardo Botti; Maurizio Del Giudice; Paolo Antonio Ascierto; Nicola Mozzillo
Journal:  Melanoma Manag       Date:  2015-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.